LinkedInXFacebook
Subscribe
Orthopedics This Week
  • My Feed
  • |Posts
  • |Events
  • |MSK Innovations
  • |Power Rankings
  • |Masterclasses
  • |Technology Awards
  • Press Releases
  • |Advertising
  • |Job Board
  • Spine
  • ◆Joints
  • ◆Upper Extremities
  • ◆Foot & Ankle
  • ◆Sports Medicine
  • ◆Pain Mgmt
  • ◆Trauma
  • ◆Biologics
  • ◆Technology
  • ◆People
  • ◆Company News
  • ◆Legal & Regulatory
Home/Spine/Implanet Launches JAZZ Evo® for Fusion
Spine

Implanet Launches JAZZ Evo® for Fusion

May 31, 2018 2 min read Premium comments

Advertisement

Implanet Launches JAZZ Evo® for Fusion
Courtesy of Implanet
Secondary#fusion#implanet#jazzevo

Implanet, based in Bordeaux, France, has announced the launch of JAZZ Evo®, a new addition to the JAZZ line of implants which address the constraints of vertebral fusion indications in adults.

Developed primarily to facilitate the treatment of degenerative pathologies in adults, JAZZ Evo is the first implant of a new range of JAZZ connectors. These connectors will be launched commercially by the company over the course of the next two years.

The implant benefits from the intellectual property protection of the JAZZ range, a system for blocking the braid with a single screw, ensuring optimum clamping on the rod without damaging the braid.

JAZZ Evo is available in three diameters representing 90 percent of diameters used in degenerative spine surgery and can be used with the JAZZ Passer Band, the braid specially designed for use in adults. Jazz Evo has already obtained CE marking and 510(K) authorization, demonstrating Implanet’s know-how in an increasingly challenging regulatory climate, in particular with the reduction in the number of certification bodies.

Régis Le Couedic, Research and Development Director at Implanet, commented, “With the aim of permanent innovation, we work in close collaboration with surgeons to develop our range and optimize the design of the JAZZ implant in order to make it even easier to use. JAZZ Evo embodies Implanet’s approach of targeting the market of degenerative disease in adults. Surgeons are often concerned about the invasive aspect of implants and the reduced size of JAZZ Evo means that its use makes surgery less invasive while also reducing the volume of metal implanted. Like all of our range, JAZZ Evo is a snap-on, auto-stable implant, which makes it easier to position. These features are protected by existing patents.”

Asked about the challenges in developing a product that blocks the braid with a single screw and doesn’t damage the braid, Ludovic Lastennet, CEO of Implanet, told OTW, “The challenge is to block the band AND the connector with a single screw. Three challenges in one actually: 1) being able to achieve a sequential locking (band first and finally connector; 2) to have enough locking strength without damaging the band fibers and, finally; 3) incorporate this mechanism in a low-profile-easy-to-use design.”

“The Band Technology has been broadly used in complex spine surgery to reduce the deformation and restore the kyphosis. The next generation of JAZZ products, starting with the launch of JAZZ Evo will be dedicated to the treatment of adult patient and more specifically in the prevention of the PJK and the saucerization of pedicle screws in patient with poor bone quality.”

React:

Discussion

14
DS
Dr. Sarah MitchellOrthopedic Surgeon · Mayo Clinic

This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?

8
JT
James Thornton, MDSpine Fellow · HSS

Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.

5
RP
R. PatelSports Medicine · Stanford

We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.

Join the conversation

Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.

Subscribe

Get Full Access

Read every OTW article and join member discussions for $24.99/month.

Get Full Access

Advertisement

Advertisement

Advertisement

Orthopedics This Week

The most trusted source in orthopedic industry news since 2005. Covering spine, joints, trauma, biologics, and the business of orthopedics.

A publication of RRY Publications, LLC

LinkedInXFacebook

Categories

  • Spine
  • Joints
  • Upper Extremities
  • Foot & Ankle
  • Sports Medicine
  • Pain Mgmt
  • Trauma
  • Biologics
  • Technology
  • People
  • Company News
  • Legal & Regulatory

Resources

  • Subscribe
  • Community Posts
  • Job Board
  • Press Release Opportunities
  • Power Rankings
  • About OTW
  • Advertise
  • Contact Us

Get Full Access

Unlimited articles, community posts, and Power Rankings.

Get Full Access

Plans start at $24.99/mo · Annual saves 20%

© 2026 Orthopedics This Week · RRY Publications, LLC

Privacy PolicyTerms of ServiceCookie Policy